瑞舒伐他汀钙对急性冠脉综合征患者血清炎症因子及内皮功能的影响

发布时间：2018-07-17 06:31

【摘要】：目的探讨瑞舒伐他汀钙对急性冠脉综合征(ACS)患者血清炎症因子及血管内皮因子的影响。方法将70例ACS患者随机平均分为对照组和观察组。两组患者均予相同的常规治疗,对照组在常规基础上加阿托伐他汀钙(20 mg/d),观察组加用瑞舒伐他汀钙(10 mg/d),两组疗程均为8 w。观察并比较两组患者在溶栓后血脂、血清炎症因子的变化及不良反应。结果两组患者治疗前各项指标比较差异无统计学意义。疗程结束后,两组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平较治疗前下降,高密度脂蛋白胆固醇(HDL-C)水平较治疗前升高,而观察组TC、TG、LDL-C下降幅度、HDL-C上升幅度较对照组更明显(P0.05)。两组患者肿瘤坏死因子(TNF)-α、基质金属蛋白酶(MMP)-9、超敏C反应蛋白(hs-CRP)、内皮素(ET)水平均较治疗前降低,一氧化氮(NO)水平较治疗前升高,但观察组炎症因子及内皮因子改善水平更显著(P0.05)。术后3个月内,观察组患者发生心绞痛3例,心肌梗死0例,心脏事件发生率为8.6%;对照组出现心绞痛3例,心肌梗死1例,心脏事件发生率为11.4%,两组患者心脏事件发生率差异无统计学意义(P0.05)。结论瑞舒伐他汀钙可有效改善ACS患者血脂水平,抑制体内炎症反应,改善损伤的血管内皮功能,降低术后3个月心脏事件发生率。
[Abstract]:Objective to investigate the effects of recuvastatin calcium on serum inflammatory and vascular endothelial factors in patients with acute coronary syndrome (ACS). Methods 70 patients with ACS were randomly divided into control group and observation group. The patients in both groups were treated with the same routine therapy. The control group was treated with Atto vastatin calcium (20 mg/d) and the observation group with rosuvastatin calcium (10 mg/d). The course of treatment was 8 wks in both groups. The changes of blood lipids, serum inflammatory factors and adverse reactions after thrombolytic therapy were observed and compared between the two groups. Results there was no significant difference between the two groups before treatment. After the course of treatment, the levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) in the two groups were lower than those before treatment. The decrease of LDL-C and the increase of HDL-C in the observation group were more obvious than those in the control group (P0.05). The levels of tumor necrosis factor (TNF)-伪, matrix metalloproteinase (MMP) -9, hypersensitive C-reactive protein (hs-CRP) and endothelin (et) in both groups were lower than those before treatment, and the levels of nitric oxide (no) were higher than those before treatment, but the levels of inflammatory factors and endothelial factors in the observation group were more significant (P0.05). Within 3 months after operation, there were 3 cases of angina pectoris, 0 cases of myocardial infarction and 8.6% of cardiac events in the observation group, while in the control group, 3 cases had angina pectoris and 1 case had myocardial infarction. The incidence of cardiac events was 11.4. There was no significant difference in the incidence of cardiac events between the two groups (P0.05). Conclusion Risuvastatin calcium can effectively improve the level of blood lipid, inhibit inflammatory reaction, improve vascular endothelial function and decrease the incidence of cardiac events in patients with ACS at 3 months after operation.
【作者单位】：宿迁市中医院心血管内科;
【分类号】：R541.4

【相似文献】